Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in platinum recurrent or refractory metastatic germ cell tumors
NCT03726281Phase 2Withdrawn
- Sponsor
- Hospital Beatriz Ângelo
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in germ cell tumor (GCT), sponsored by Hospital Beatriz Ângelo. Planned start Oct 2018; status: withdrawn.
02
Drugs
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT03726281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726281.